In January 2025, Sagimet delivered an oral presentation at the 9 th Annual MASH-TAG Conference highlighting the ...

Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins Underscores Radiopharm’s commitment to developing ...

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has released its Q1 earnings. Here is a breakdown of the information Sagimet Biosciences, Inc. Class ...

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases ...

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...

SGMT), clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in ...

The gene interacts with two key enzymes: ACETYL-COENZYME A CARBOXYLASE CARBOXYLTRANSFERASE ALPHA SUBUNIT (α-CT), which is essential for fatty acid biosynthesis, and STARCH SYNTHASE 4 (SS4), which ...

Researchers at Peking University have discovered that a filamentous gut fungus, Fusarium foetens, can reverse metabolic ...